3Li L,Haynes MP,Bender JR.Plasma membrane localization and function of the estrogen receptor alpha variant(ER46)in human endothelial cells[J].Proc Natl Acad Sci USA,2003,100 (8):4807-4812.
4Levin ER.Cellular functions of plasma membrane estrogen re-ceptors[J].Steroids.2002,67(6):471-475.
5Cheskis BJ,Greger JG,Nagpal,et al.Signaling by estrogens[J].J Cell Physiol,2007,213(3):610-617.
6Bord S,Homer A,Beavan S,et al.Estrogen receptors a and β are differential expressed in developing human bone[J].J Clin Endocrinol Metab,2001,86(5):2309-2314.
8Rossouw JE,Anderson GL,Prentice RL,et al.Risks 8nd bene-fits of estrogen plus progestin in healthy postmenopausal woment principal results from the Women's Heahh Initiative randomized controHed trial[J].JAMA,2002,288(3):321-333.
9Verborgt O,Gibson GJ,Schaffer MB.Loss of osteocytes integ-rity with microdamage and bone remodeling after fatigue in vivo[J].J Bone Miner Res,2000,15(1):60-67.
10Gruber CJ,Tschugguel W,Schneeburger C.et al.Production and actions of estrogens[J].N Engl J Med,2002,346(5):340-352.
8[1]Slemenoa CW, Fohnston CC JR. Epidemiology ofosteoporosis, in Lobo RA(ed) .treatment of the bostmenopausal woman: basic and linica a.spects. New York: Raven Press 1994:161 -8
9[3]Nurse P. Collaborative group on hormonal factors in breast cancer. breast cancer and HRT: collaborative reanalysis of data form 51 epidemiological studies of 52705 women with breast cance. Lancet 1997; 350(9091 ): 1047 - 59
10Lips P,Cooper C.Wiklund I.Quality of life as outcome in the treatment ofosteoporosis:the development of a questionnaire for quality of life by the European Foundationfor Osteoporosis.Osteoporosis International.1997.7 (1):36
